Placebo + RG1662 + RG1662
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Down Syndrome
Conditions
Down Syndrome
Trial Timeline
May 5, 2014 → May 4, 2016
NCT ID
NCT02024789About Placebo + RG1662 + RG1662
Placebo + RG1662 + RG1662 is a phase 2 stage product being developed by Roche for Down Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02024789. Target conditions include Down Syndrome.
What happened to similar drugs?
1 of 3 similar drugs in Down Syndrome were approved
Approved (1) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02024789 | Phase 2 | Completed |
Competing Products
13 competing products in Down Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg) | Yuhan | Phase 1 | 29 |
| Aricept (donepezil hydrochloride) + Aricept (donepezil hydrochloride) + Placebo | Eisai | Phase 3 | 32 |
| Aricept (Donepezil hydrochloride) + Placebo | Eisai | Phase 3 | 32 |
| Donepezil hydrochloride (Aricept) | Eisai | Phase 2 | 27 |
| E2020-Donepezil hydrochloride + E2020-Donepezil hydrochloride + Placebo | Eisai | Phase 2 | 35 |
| Donepezil HCl + Placebo | Eisai | Phase 2 | 35 |
| Donanemab + Placebo | Eli Lilly | Approved | 50 |
| Placebo + RG1662 | Roche | Phase 1 | 29 |
| Placebo + RO5186582 | Roche | Phase 2 | 27 |
| RG1662 + placebo | Roche | Phase 1 | 29 |
| ELND005 + Placebo | Elanco | Phase 2 | 32 |
| ACI-24 low dose + ACI-24 high dose + Placebo | AC Immune | Phase 1 | 19 |
| ACI-24 + Placebo | AC Immune | Phase 2 | 17 |